TY - JOUR
T1 - Efficacy of cetuximab in the treatment of ménétrier's disease
AU - Fiske, William H.
AU - Tanksley, Jarred
AU - Nam, Ki Taek
AU - Goldenring, James R.
AU - Slebos, Robbert J.C.
AU - Liebler, Daniel C.
AU - Abtahi, Amir M.
AU - Fleur, Bonnie La
AU - Ayers, Gregory D.
AU - Lind, Christopher D.
AU - Washington, Mary K.
AU - Coffey, Robert J.
PY - 2009/11/25
Y1 - 2009/11/25
N2 - Ménétrier's disease is a rare premalignant disorder of the stomach with no proven effective medical therapy. Increased epidermal growth factor receptor signaling has been implicated in the pathogenesis of Ménétrier's disease. We conducted a single-arm clinical trial with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor signaling, in nine individuals with clinically and histologically documented severe Ménétrier ' s disease that impaired quality of life to the extent that gastrectomy was being considered. Of the seven patients who completed the 1-month course of treatment, all showed statistically significant improvement both clinically (quality-of-life indices) and biochemically (increased parietal cell mass and gastric acidity). Furthermore, all seven patients who completed the 1-month trial elected to continue treatment, and four subsequently showed near-complete histological remission. Cetuximab should be considered as first-line therapy for Ménétrier's disease.
AB - Ménétrier's disease is a rare premalignant disorder of the stomach with no proven effective medical therapy. Increased epidermal growth factor receptor signaling has been implicated in the pathogenesis of Ménétrier's disease. We conducted a single-arm clinical trial with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor signaling, in nine individuals with clinically and histologically documented severe Ménétrier ' s disease that impaired quality of life to the extent that gastrectomy was being considered. Of the seven patients who completed the 1-month course of treatment, all showed statistically significant improvement both clinically (quality-of-life indices) and biochemically (increased parietal cell mass and gastric acidity). Furthermore, all seven patients who completed the 1-month trial elected to continue treatment, and four subsequently showed near-complete histological remission. Cetuximab should be considered as first-line therapy for Ménétrier's disease.
UR - http://www.scopus.com/inward/record.url?scp=77952388508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952388508&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3000320
DO - 10.1126/scitranslmed.3000320
M3 - Article
C2 - 20368185
AN - SCOPUS:77952388508
VL - 1
JO - Science Translational Medicine
JF - Science Translational Medicine
SN - 1946-6234
IS - 8
M1 - 8ra18
ER -